Retifanlimab
- Generic Name
- Retifanlimab
- Brand Names
- Zynyz
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2079108-44-2
- Unique Ingredient Identifier
- 2Y3T5IF01Z
- Background
Retifanlimab is a humanized IgG4 kappa monoclonal antibody that binds to the programmed death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells...
- Indication
Retifanlimab is indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma.
- Associated Conditions
- Metastatic Locally Advanced Merkel Cell Carcinoma, Recurrent, locally advanced Merkel Cell Carcinoma
- Associated Therapies
- -
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
- Conditions
- Interventions
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Stephen Bagley, MD, MSCE
- Target Recruit Count
- 55
- Registration Number
- NCT05345002
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Incyte Biosciences International SÃ rl
- Target Recruit Count
- 176
- Registration Number
- NCT05287113
- Locations
- 🇬🇷
Saint Lukas Clinic, Thessaloniki, Greece
🇵🇱Przychodnia Lekarska Komed Roman Karaszewski, Konin, Poland
🇵🇱Nzoz Provita Prolife Centrum Medyczne, Tomaszow Mazowiecki, Poland
9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Anwaar Saeed
- Target Recruit Count
- 32
- Registration Number
- NCT05239182
- Locations
- 🇺🇸
Kansas University Cancer Center, Fairway, Kansas, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)
- Conditions
- Interventions
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2024-08-02
- Target Recruit Count
- 25
- Registration Number
- NCT05177133
- Locations
- 🇳🇱
Amsterdam UMC, location VUmc, Amsterdam, Netherlands
🇳🇱Academic Medical Center, Medical Oncology, Amsterdam, Netherlands
🇳🇱Medisch Centrum Leeuwarden, Leeuwarden, Netherlands
Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2024-11-06
- Target Recruit Count
- 50
- Registration Number
- NCT05083754
- Locations
- 🇺🇸
Johns Hopkins Medical Institution, Baltimore, Maryland, United States
Study of INCA 0186 in Subjects With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 57
- Registration Number
- NCT04989387
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇧🇪Universitair Ziekenhuis Antwerpen (Uza), Edegem, Belgium
🇳🇱University Medical Center Groningen, Groningen, Netherlands
The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
- Conditions
- Interventions
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT04949191
- Locations
- 🇺🇸
Virginia Cancer Specialists, Pc, Fairfax, Virginia, United States
🇺🇸Oncology Specialists of Charlotte, Charlotte, North Carolina, United States
🇮🇹Istituto Nazionale Tumori Regina Elena Irccs, Rome, Italy
Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer
- Conditions
- Interventions
An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT04586244
- Locations
- 🇮🇹
Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico Bari, Bari, Italy
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
🇫🇷Institut Gustave Roussy, Villejuif Cedex, France
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2020-10-06
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 67
- Registration Number
- NCT04577014
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.